Mechanism based pharmacometric analysis can be a powerful tool in the development of biosimilar drugs. Pharmetheus recently supported a client with evaluating the impact of study design and expected product differences on the power to demonstrate PK and PD similarity. Find out more in a recent paper by Ari Brekkan et al. AAPS J. 2019 Jul 8;21(5):85.

We are glad to announce that Ida Netterberg (MIDD consultant) is returning to Pharmetheus after recently defending her PhD thesis at Uppsala University. Ida’s thesis focused on pharmacometric evaluation of biomarkers to improve treatment in oncology. See Ida's bio here.

We are happy to welcome Ola Caster in our growing enabler team. Ola comes most recently from a position as a Senior Researcher at the Uppsala Monitoring Centre, where he worked primarily with methods for adverse effect detection and benefit-risk assessment in the post-marketing setting. He has more than ten years of experience from research in statistics and data science, including a PhD in Computer and Systems Sciences. See Ola's bio here.

The Pharmetheus team has recently been strengthened by our first dedicated Project Coordinator, Marie Karlsson. Marie has long prior experience in monitoring data processing and project management in software development. See Marie's bio here. Welcome!

Come meet us at ACoP in Orlando next week. Drop by our booth to discuss model informed drug development with our experts and leaders. There are still opportunities for free speed consulting, should you want input to your strategic or hands-on work.

This year, during the ACOP Meeting in Orlando, Pharmetheus will offer professional pharmacometric consulting sessions (~30 min), free of charge. Talk to us about Pharmacometrics, PBPK, Regulatory strategy, MIDD strategy, and much more! These sessions are open to everyone and independent of any current or future plans to use our services.